Real-life use of delamanid: results from the European post-authorisation safety study

Real-life use of delamanid: results from the European post-authorisation safety study

BACKGROUND: A post-authorisation safety study (PASS) on delamanid (DLM) was conducted as part of a post-approval commitment to the European Medicines Agency. The aim of this study was to evaluate the use of DLM in a real-life setting, its safety, and treatment outcomes in patients with multidrug-res...

Full description

Saved in:
Bibliographic Details
Main Authors: N. Schönfeld, L. Barkane, I. Davoliene, M. Danilovits, S. Miliauskas, F. Ader, O.M. Kon, C. Lange, A. Duvignaud, M. Heiss-Neumann, N. Hittel, N. Lazarević, I. Knebel, A. Martin, B. Eschenbach, E. van Heumen, V. George
Format: Article
Language:English
Published: International Union Against Tuberculosis and Lung Disease (The Union) 2024-06-01
Series:IJTLD Open
Subjects:
tuberculosis
multidrug-resistant tuberculosis
mdr-tb
pass
safety treatment outcomes
adverse events
european medicines agency
Online Access:https://www.ingentaconnect.com/contentone/iuatld/ijtldo/2024/00000001/00000006/art00006
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items